Kemwell Biopharma & RevOpsis partner to expedite development of novel multispecific biologics

17 June 2024 | News

Development of first-in-class tri-specific biologic for treating neovascular age-related macular degeneration

RevOpsis Therapeutics, a US-based next-generation biopharmaceutical startup spearheading innovation of multispecific ophthalmic therapies, and Bengaluru-based Kemwell Biopharma, a leading biologics contract development and manufacturing organization (CDMO), have announced a broad strategic manufacturing partnership.

This collaboration aims to accelerate the development of RevOpsis' lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).

Under this partnership, Kemwell will manufacture RO-104, a novel tri-specific biologic designed to target the three dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) for treating nAMD, a leading cause of blindness worldwide. The unique ability of RO-104 to bind these three validated targets simultaneously positions it as a first-in-class fully human monotherapy biologic, poised to redefine the treatment landscape for retinal vascular diseases.

As India's first commercial current Good Manufacturing Practices (cGMP) manufacturing facility, Kemwell is a trusted and respected partner with extensive experience in complex protein manufacturing. This collaboration leverages Kemwell's well-established manufacturing excellence and RevOpsis' innovative Rev-Mod platform to expedite the development of novel multispecific biologics.

This new alliance provides RevOpsis a critical biologics development solution to rapidly transition from pre-clinical activities to first-in-human clinical trials, expediting the development of RO-104 and the broader platform. By integrating RevOpsis' next generation plug-and-play multispecific biologics platform with Kemwell's deep biologics development and manufacturing knowledge, the collaboration aims to accelerate therapeutic discovery to IND submission timelines.